Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

V-902

Supelco

Vardenafil dihydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H32N6O4S·2HCl
Numéro CAS:
224785-90-4
Poids moléculaire :
561.52
Numéro CE :
200-659-6
Numéro MDL:
MFCD04972607
Code UNSPSC :
41116107
ID de substance PubChem :
329830239
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol (as free base)

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

pharmaceutical (small molecule)

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

O=C(C1=C(C)N=C(CCC)N1N2)N=C2C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC.Cl.Cl

InChI

1S/C23H32N6O4S.2ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);2*1H

Clé InChI

NOIHTGOGFDFCBN-UHFFFAOYSA-N

Informations sur le gène

human ... PDE5A(8654)

Description générale

Vardenafil, a phosphodiesterase inhibitor, is used to treat erectile dysfunction. This Snap-N-Spike® reference solution is applicable for use in urine drug testing, clinical toxicology or forensic analysis by LC-MS/MS or GC/MS. Vardenafil is sold under the trade names Levitra® and Staxyn®.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Levitra is a registered trademark of Bayer Aktiengesellschaft
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Staxyn is a registered trademark of Bayer Aktiengesellschaft

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

USP

USP

1711029

Vardenafil System Suitability

Daniel J Mans et al.
Journal of pharmaceutical and biomedical analysis, 75, 153-157 (2012-12-25)
Ion mobility spectrometry was used as a rapid screening tool for the detection of acetildenafils, sildenafils and avanafil within adulterated herbal supplement matrices. Acetildenafils show a tendency for partial fragmentation during the desorption/ionization process affording two peaks in the ion
Kenneth Beer
Journal of drugs in dermatology : JDD, 11(12), 1494-1495 (2013-02-05)
Eruptions from drugs are among the most frequently reported adverse events. The most frequent etiologic agents include antibiotics and nonsteroidal anti-inflammatory agents. These eruptions are also a frequent source of visits to dermatology of!ces. Many of the inciting agents are
S I Gamidov et al.
Urologiia (Moscow, Russia : 1999), (3)(3), 102-104 (2013-08-31)
Due to high efficiency, prompt action and low incidence of side effects, phosphodiesterase type 5 inhibitors are the drugs of first choice in the treatment of erectile dysfunction (ED). One of the most widely used drugs in this group currently
[New Levitra in the treatment of erectile dysfunction].
A L Vertkin et al.
Urologiia (Moscow, Russia : 1999), (6)(6), 100-102 (2013-02-06)
Christoph Zenzmaier et al.
Endocrinology, 153(11), 5546-5555 (2012-09-06)
Phosphodiesterase type 5 (PDE5) inhibitors have been demonstrated to improve lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Because BPH is primarily driven by fibroblast-to-myofibroblast trans-differentiation, this study aimed to evaluate the potential of the PDE5 inhibitor vardenafil
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique